Cardinal Health, Inc. (CAH) CEO Mike Kaufmann on Q3 2022 Results - Earnings Call Transcript

Cardinal Health, Inc. (NYSE:CAH) Q3 2022 Earnings Conference Call May 5, 2022 8:30 AM ET

Corporate Participants

Kevin Moran - Vice President, Investor Relations

Mike Kaufmann - Chief Executive Officer

Jason Hollar - Chief Financial Officer

Conference Call Participants

Charles Rhyee - Cowen

Eric Percher - Nephron Research

Michael Cherny - Bank of America

Lisa Gill - JPMorgan

Ricky Goldwasser - Morgan Stanley

Elizabeth Anderson - Evercore ISI

George Hill - Deutsche Bank

AJ Rice - Credit Suisse

Eric Coldwell - Baird

Steven Valiquette - Barclays

Operator

Good day and welcome to the Cardinal Health, Inc. Third Quarter Fiscal Year 2022 Earnings Conference Call. Today’s conference is being recorded.

At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor Relations. Please go ahead.

Kevin Moran

Good morning. Today, we will discuss Cardinal Health third quarter fiscal 2022 results along with an update to our FY’22 outlook. You can find today’s press release and presentation on the IR section of our website at ir.cardinalhealth.com.

Joining me today are Mike Kaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.

During the call, we will be making forward-looking statements. The matters addressed in these statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statements slide at the beginning of our presentation for a description of these risks and uncertainties.

Please note that during our discussion today, our comments will be on a non-GAAP basis unless they are specifically called out as GAAP. GAAP to non-GAAP reconciliation for all relevant periods can be found in the schedules attached to our press release. During the Q&A portion of today’s call, we please ask that you try and limit yourself to one question so that we can try and give everyone an opportunity.

With that, I will now turn the call over to Mike.

Mike Kaufmann

Thanks, Kevin, and good morning, everyone.

Our third quarter results reflect continued inflationary impacts and global supply chain constraints. As we continue to manage through the current macroeconomic environment, we remain focused on both near-term priority and long-term strategies to drive growth and momentum across our businesses.

At an enterprise level, we're maintaining our focus on our three strategic priorities, optimizing our core businesses, investing for growth and innovation, and deploying capital efficiently. In pharma, despite the quarter being a little lower, due to higher operations costs, we remain encouraged by the trajectory of the business. We saw resiliency and overall pharmaceutical demand, strong performance in our generics program and continue to expect pharma to realize mid-single digit profit growth in FY '22.